Sobi, Valeant sign new agreement for UCDs drug distribution

Swedish Orphan Biovitrum (Sobi) has entered into a 3-year agreement with Ireland’s Valeant Pharmaceuticals for the distribution of Ammonul injection, an acute Urea Cycle Disorders (UCDs) drug, in Europe, the Middle East and North Africa.

Acording to agreement, Sobi will have exclusive rights and license for sales and distribution of Ammonul in Europe, the Middle East and North Africa until 31 December 2019 for named patient use (NPU) programmes.

Alan Raffensperger, Chief Operating Officer at Sobi said: “This agreement complements Sobi’s portfolio within the area of Urea Cycle Disorders and creates a wider range of treatment alternatives for patients suffering from these rare conditions”. 

Ammonul is approved by the US Food and Drug Administration (FDA) for the treatment of acute UCDs. The product is not registered in the European Union, Middle East or North Africa but is only available under NPU programmes.